Citations

Clear

15 citation(s) found for "Shi, Jiang".

Pig-to-human lung xenotransplantation in a brain-dead human recipient
Liu, Xiaoyou , Peng, Guilin, Shi, Jiang , Ju, Chunrong, He, Ping , Liu, Xiaoqing , Zhang, Zuopen, Chen, Chuanbao, Pan, Dengke, Yang, Zifeng , Guan, Wenda, 陈, 中华克劳斯, Liu, Menyang, Liang, Hengrui , Zhao, Yi , Huang, Weiqing , Rucker, A. Justin , Xu, Xin , He, Jianxing , Yang, Chao , Liu, Hui, Liu, Xiaoqing, Zhang, Zuopeng , Pan, Dengke , Yang, Zifeng , Guang, Wenda, Li, Hongtao , Chen, Zhonghua, Liang, Hengrui , Jeon, Kyeongman , Chen-Yoshikawa, Toyofumi Fengshi , Lal, Amos, Zhang, Kang , Zhang, Kang , Liu, Xiaoyou , Xu, Xin

Mayo Clinic

No container title available | November 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5155123/v1 Get It

Abstract This study reports the first pig-to-human lung xenotransplantation using a six gene-edited pig lung. A left lung from a gene-edited Chinese Bama Xiang pig was transplanted into a 39-year-old brain-dead human recipient. The xenograft maintained viability and functionality for 216 hours without signs of hyperacute rejection. Postoperatively, severe edema resembling primary graft dysfunction (PGD) was observed, potentially due to ischemia-reperfusion injury. Antibody-mediated rejection appeared to contribute to xenograft damage on postoperative days 3 and 6, with partial recovery by day 9 under the current immunosuppressive regimen. This pioneering study suggests that genetically modified pig lungs could potentially be used for future clinical applications in xenotransplantation.
Aberrant Gene Regulation in Obstetric, Gynecologic, and Reproductive Diseases
Jiang, Shi‐Wen , Brost, Brian , Zhang, Dan , Ren, Chune

Mayo Clinic

BioMed Research International | August 23, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-2

10.1155/2015/187691 | PMID 26366409 Get It

Microarray Analysis on Gene Regulation by Estrogen, Progesterone and Tamoxifen in Human Endometrial Stromal Cells
Ren, Chun-E, Li, Jin‐Ping , Lyle, Christian, Dowdy, Sean C. , Podratz, Karl C. , Byck, David, Chen, Hai-Bin, Jiang, Shi-Wen, Chen, Hai-Bin , Dowdy, Sean, Zhu, Xueqiong , Jiang, Shi‐Wen

Mayo Clinic

International Journal of Molecular Sciences | March 13, 2015 | Volume: 16 | Issue: 3 | Pages: 5864-5885

10.3390/ijms16035864 | PMID 25782154 Get It

Epithelial stromal cells represent a major cellular component of human uterine endometrium that is subject to tight hormonal regulation. Through cell-cell contacts and/or paracrine mechanisms, stromal cells play a significant role in the malignant transformation of epithelial cells. We isolated stromal cells from normal human endometrium and investigated the morphological and transcriptional changes induced by estrogen, progesterone and tamoxifen. We demonstrated that stromal cells express appreciable levels of estrogen and progesterone receptors and undergo different morphological changes upon hormonal stimulation. Microarray analysis indicated that both estrogen and progesterone induced dramatic alterations in a variety of genes associated with cell structure, transcription, cell cycle, and signaling. However, divergent patterns of changes, and in some genes opposite effects, were observed for the two hormones. A large number of genes are identified as novel targets for hormonal regulation. These hormone-responsive genes may be involved in normal uterine function and the development of endometrial malignancies.
Human Placental TEF-5 Transactivates the Human Chorionic Somatomammotropin Gene Enhancer
Jiang, Shi-Wen, Wu, Kangjian, Eberhardt, Norman L., Jiang, Shi‐Wen

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 13 | Issue: 6 | Pages: 879-889

10.1210/mend.13.6.0288 | PMID 10379887 Get It

Human Chorionic Somatomammotropin Enhancer Function Is Mediated by Cooperative Binding of TEF-1 and CSEF-1 to Multiple, Low-Affinity Binding Sites
Jiang, Shi-Wen, Trujillo, Miguel A., Eberhardt, Norman L., Jiang, Shi‐Wen

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 11 | Issue: 9 | Pages: 1223-1232

10.1210/mend.11.9.9984 | PMID 9259314 Get It

HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival
Jiang, Shi-Wen, Chen, Hai-Bin , Dowdy, Sean C. , Fu, Alex Z., Attewell, John R., Kalogera, Eleftheria , Drapkin, Ronny , Podratz, Karl C. , Broaddus, Russell R. , Li, Jinping , Jiang, Shi‐Wen , Drapkin, Ronny

Mayo Clinic

International Journal of Molecular Sciences | November 19, 2013 | Volume: 14 | Issue: 11 | Pages: 22655-22677

10.3390/ijms141122655 | PMID 24252907 Get It

We investigated the HE4 variant-specific expression patterns in various normal tissues as well as in normal and malignant endometrial tissues. The relationships between mRNA variants and age, body weight, or survival are analyzed. ICAT-labeled normal and endometrial cancer (EC) tissues were analyzed with multidimensional liquid chromatography followed by tandem mass spectrometry. Levels of HE4 mRNA variants were measured by real-time PCR. Mean mRNA levels were compared among 16 normal endometrial samples, 14 grade 1 and 14 grade 3 endometrioid EC, 15 papillary serous EC, and 14 normal human tissue samples. The relationship between levels of HE4 variants and EC patient characteristics was analyzed with the use of Pearson correlation test. We found that, although all five HE4 mRNA variants are detectable in normal tissue samples, their expression is highly tissue-specific, with epididymis, trachea, breast and endometrium containing the highest levels. HE4-V0, -V1, and -V3 are the most abundant variants in both normal and malignant tissues. All variants are significantly increased in both endometrioid and papillary serous EC, with higher levels observed in grade 3 endometrioid EC. In the EC group, HE4-V1, -V3, and -V4 levels inversely correlate with EC patient survival, whereas HE4-V0 levels positively correlate with age. HE4 variants exhibit tissue-specific expression, suggesting that each variant may exert distinct functions in normal and malignant cells. HE4 levels appear to correlate with EC patient survival in a variant-specific manner. When using HE4 as a biomarker for EC management, the effects of age should be considered.
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
Li, Jinping , Mariani, Andrea , Chen, Dong , Klatt, Edward, Podratz, Karl C. , Drapkin, Ronny , Broaddus, Russell R. , Dowdy, Sean C. , Jiang, Shi‐Wen , Chen, Hai-Bin , Chen, Haibin , Klatt, Edward, Chen, Dong , Drapkin, Ronny

Mayo Clinic

International Journal of Molecular Sciences | March 15, 2013 | Volume: 14 | Issue: 3 | Pages: 6026-6043

10.3390/ijms14036026 | PMID 23502467 Get It

HE4, also known as WFDC2, is a useful biomarker for ovarian cancer when either used alone or in combination with CA125. HE4 is also overexpressed in endometrial cancer (EC), but its function in cancer cells is not clear. In this study, we investigate the role of HE4 in EC progression. An HE4-overexpression system was established by cloning the HE4 prototypic mRNA variant (HE4-V0) into a eukaryotic expression vector. Following transfection, stable clones in two EC cell lines were selected. The effects of HE4 overexpression on cell growth and function were measured with the use of cell proliferation assay, matrigel invasion, and soft agar gel colony formation assays. HE4-induced cancer cell proliferation in vivo was examined in a mouse xenograft model. HE4 overexpression significantly enhanced EC cell proliferation, matrigel invasion, and colony formation in soft agar. Moreover, HE4 overexpression promoted tumor growth in the mouse xenograft model. HE4 overexpression enhanced several malignant phenotypes in cell culture and in a mouse model. These results are consistent with our previous observation that high levels of serum HE4 closely correlate with the stage, myometrial invasion and tumor size in patients with EC. This study provides evidence that HE4 overexpression directly impacts tumor progression in endometrial cancer.
Biologic properties and enucleation of red blood cells from human embryonic stem cells
Lu, Shi-Jiang, Park, Jennifer S., Vida, Loyda N., Lee, Bao-Shiang, Strausbauch, Michael, Wettstein, Peter J., Honig, George R., Lanza, Robert , Lu, Shi‐Jiang, Feng, Qiang

Mayo Clinic

Blood | August 20, 2008 | Volume: 112 | Issue: 12 | Pages: 4475-4484

10.1182/blood-2008-05-157198 | PMID 18713948 Get It

Abstract Human erythropoiesis is a complex multistep process that involves the differentiation of early erythroid progenitors to mature erythrocytes. Here we show that it is feasible to differentiate and mature human embryonic stem cells (hESCs) into functional oxygen-carrying erythrocytes on a large scale (1010-1011 cells/6-well plate hESCs). We also show for the first time that the oxygen equilibrium curves of the hESC-derived cells are comparable with normal red blood cells and respond to changes in pH and 2,3-diphosphoglyerate. Although these cells mainly expressed fetal and embryonic globins, they also possessed the capacity to express the adult β-globin chain on further maturation in vitro. Polymerase chain reaction and globin chain specific immunofluorescent analysis showed that the cells increased expression of β-globin (from 0% to > 16%) after in vitro culture. Importantly, the cells underwent multiple maturation events, including a progressive decrease in size, increase in glycophorin A expression, and chromatin and nuclear condensation. This process resulted in extrusion of the pycnotic nuclei in up to more than 60% of the cells generating red blood cells with a diameter of approximately 6 to 8 μm. The results show that it is feasible to differentiate and mature hESCs into functional oxygen-carrying erythrocytes on a large scale.
Protein Kinase C-Mediated Modulation of FIH-1 Expression by the Homeodomain Protein CDP/Cut/Cux
Li, Jin‐Ping , Wang, Enfeng , Dutta, Shamit K., Lau, Julie S., Jiang, Shi-Wen, Datta, Kaustubh , Jiang, Shi‐Wen , Mukhopadhyay, Debabrata

Mayo Clinic

Molecular and Cellular Biology | August 7, 2007 | Volume: 27 | Issue: 20 | Pages: 7345-7353

10.1128/mcb.02201-06 | PMID 17682059 Get It

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells
Dowdy, Sean C. , Zhou, Xuanting , Hou, Xiaonan , Jin, Fan , Podratz, Karl C. , Jiang, Shi-Wen, Jiang, Shujuan , Jiang, Shi‐Wen

Mayo Clinic

Molecular Cancer Therapeutics | November 22, 2006 | Volume: 5 | Issue: 11 | Pages: 2767-2776

10.1158/1535-7163.mct-06-0209 | PMID 17121923 Get It

Abstract The use of histone deacetylase (HDAC) inhibitors has shown promise for a variety of malignancies. In this investigation, we define the activity of this class of inhibitors in combination with traditional cytotoxic chemotherapy in endometrial cancer cells. Significant reductions in growth were observed in Ark2 and KLE endometrial cancer cells following treatment with paclitaxel, doxorubicin, carboplatin, or the HDAC inhibitor trichostatin A (TSA). However, only combined treatment with TSA/paclitaxel caused synergistic inhibition of cell growth. This combination also resulted in significant changes in cell morphology. Using cell cycle analysis, nuclear staining, and Western blot analysis for poly(ADP-ribose) polymerase and caspase-9 degradation products, TSA/paclitaxel showed the most dramatic activation of the apoptotic cascade. These effects were also observed when the HDAC inhibitors HDAC inhibitor-1 or oxamflatin were substituted for TSA. The anticancer properties of paclitaxel are known to result in part from inhibition of microtubule depolymerization, which results in apoptosis. We show that TSA administration also stabilizes microtubules via α-tubulin acetylation. Furthermore, using Western blot and immunohistochemical analysis, treatment with TSA/paclitaxel led to a significant increase in acetylated tubulin and microtubule stabilization. These effects were confirmed in a mouse xenograft model. Moreover, TSA/paclitaxel resulted in a 50% reduction in tumor weight compared with either agent alone. This study provides in vivo evidence of nonhistone protein acetylation as one possible mechanism by which HDAC inhibitors reduce cancer growth. The TSA/paclitaxel combination seems to hold promise for the treatment of serous endometrial carcinoma and other malignancies with limited sensitivity to paclitaxel. [Mol Cancer Ther 2006;5(11):2767–76]